PDCD1 and hepatocellular carcinoma: The use of anti-PD-1/PD-L1 antibodies (pembrolizumab, durvalumab, nivolumab, sintilimab, and camrelizumab) and anti-CTLA-4 antibodies (tremelimumab and ipilimumab) as immunotherapy have shown potential for treating HCC patients.